- Home
- EDIT vs GCO Comparison
EDIT vs GCO Comparison
Compare EDIT & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- GCO
- Stock Information
- Founded
- EDIT 2013
- GCO 1924
- Country
- EDIT United States
- GCO United States
- Employees
- EDIT N/A
- GCO N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- GCO Clothing/Shoe/Accessory Stores
- Sector
- EDIT Health Care
- GCO Consumer Discretionary
- Exchange
- EDIT Nasdaq
- GCO Nasdaq
- Market Cap
- EDIT 179.1M
- GCO 212.2M
- IPO Year
- EDIT 2016
- GCO N/A
- Fundamental
- Price
- EDIT $2.75
- GCO $22.50
- Analyst Decision
- EDIT Buy
- GCO Hold
- Analyst Count
- EDIT 12
- GCO 2
- Target Price
- EDIT $6.20
- GCO $24.50
- AVG Volume (30 Days)
- EDIT 3.3M
- GCO 241.0K
- Earning Date
- EDIT 08-06-2025
- GCO 09-05-2025
- Dividend Yield
- EDIT N/A
- GCO N/A
- EPS Growth
- EDIT N/A
- GCO N/A
- EPS
- EDIT N/A
- GCO N/A
- Revenue
- EDIT $35,837,000.00
- GCO $2,341,438,000.00
- Revenue This Year
- EDIT N/A
- GCO $2.53
- Revenue Next Year
- EDIT N/A
- GCO $2.01
- P/E Ratio
- EDIT N/A
- GCO N/A
- Revenue Growth
- EDIT N/A
- GCO 1.85
- 52 Week Low
- EDIT $0.91
- GCO $16.19
- 52 Week High
- EDIT $6.05
- GCO $44.80
- Technical
- Relative Strength Index (RSI)
- EDIT 61.68
- GCO 52.29
- Support Level
- EDIT $2.48
- GCO $21.26
- Resistance Level
- EDIT $3.24
- GCO $24.63
- Average True Range (ATR)
- EDIT 0.26
- GCO 1.06
- MACD
- EDIT 0.02
- GCO 0.20
- Stochastic Oscillator
- EDIT 57.94
- GCO 57.49
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.